Cephalon Sues Eagle Over Plans For Liquid Treanda

Law360, New York (October 23, 2013, 3:07 PM EDT) -- Cephalon Inc. hit competitor Eagle Pharmaceuticals Inc. with a suit Monday in a Delaware federal court alleging that Eagle is infringing a Cephalon patent by filing a new drug application for a liquid concentrate version of Cephalon's cancer drug Treanda.

The complaint says that N.J.-based Eagle's filing of a new drug application last month with the U.S. Food and Drug Administration for a liquid version of bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma, infringes Pa.-based Cephalon's U.S. Patent Number 8,445,524.

“[Cephalon] will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.